NCT01293357已完成1 期
A Phase 1 Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects A Single Centre, Randomised, Controlled, Investigator Blinded Study With Intra-individual Comparison of the Active Formulation and Its Components
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Skin irritation
研究概览
简要总结
The objective of the trial is to investigate skin irritation, phototoxicity and safety of LEO 90105 and its components by patchtest (48 hours closed patch test and photo patch test) in healthy Japanese male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Japanese male subjects,
- •Aged 20 to 40 years inclusive.
- •Subjects without signs of skin irritation (erythema,dryness, roughness or scaling) on test sites.
- •Subjects willing to follow the study procedures and complete the study Subjects having understood and signed a written informed consent.
- •Subjects without abnormal in physiological test and clinical test in screening, and also judged as possible to participant the study by investigators.
排除标准
- •Body mass Index (BMI ) (body weight (kg)/height(m)²) outside the range 18-25 kg/m2
- •History of alcohol, chemical or drug abuse
- •History of allergic reaction to drugs or history of skin reaction to the tape
- •Any systemic or cutaneous disease that could in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, psoriasis)
- •Known sensitivity to any component of any of the formulations being tested
- •Known hepatic or renal disorders
- •Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of study start (Day 1)
- •Use of systemic vitamin D analogues, vitamin D or calcium supplements within 4 weeks of study start(Day 1)
- •Use of any drug (systemic or topical) within 2 weeks of study start (Day 1)
- •Use of non-marketed/other investigational products one month prior to or 5 half lives (for those the half life is longer than one month) and during the trial is not permitted
- •Any abnormality found at medical interview before administration of the test drug, which will affect the clinical study as judged by the investigator
- •History of or active photo-induced or photoaggravated disease (abnormal response to the sun light)
- •Exposure to excessive or chronic ultraviolet (UV)radiation (i.e., sunbathing, tanning salon use, phototherapy)within four weeks prior to inclusion (Day 1) or planned during the study period
- •Scars, moles, sunburn, or other blemishes in the test area which would interfere with grading
- •Subjects whose partner wishes to become pregnant but is unwilling to use birth control during the study
- •Any condition which, in the opinion of the investigator, would place the subject at an unacceptable risk if he participated in the study
- •Any disease which are contradictions for treatment of the investigation products or for which treatment with the investigation products needs to be carefully considered (Subjects with any of the following conditions present on the area(s) to be treated with study medication: viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds).
研究组 & 干预措施
Patches
Experimental
干预措施: LEO 90105 (Drug)
结局指标
主要结局
Skin irritation
时间窗: 5 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Assessment of the Phototoxic Potential of LEO 29102 CreamAtopic DermatitisNCT00958516LEO Pharma32
已完成
1 期
Clinical Evaluation of the Phototoxic Potential of Xenaderm OintmentHealthyNCT00644917Healthpoint38
Unknown
1 期
Study Will Assess Skin Irritation and Sensitization for HP-1050 PatchCumulative Irritation and SensitizationNCT04624867Noven Pharmaceuticals, Inc.240
已完成
1 期
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by HistologyActinic KeratosisNCT01387711LEO Pharma27
已完成
1 期
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy VolunteersActinic KeratosisNCT00850811Peplin30